Montelukast With Status Asthmaticus, Ages 6-18

NCT ID: NCT00494572

Last Updated: 2008-12-16

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 52 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-12-31
• Study Completion Date: 2010-10-31

Brief Summary

The purpose of this study is to determine if montelukast, in addition to standard treatment is helpful in treating patients ages 6-18 who are in the hospital because of status asthmaticus.

Detailed Description

This is a prospective study of montelukast efficacy in addition to standard treatment of status asthmaticus in children who are in the PICU. The study will be stratified in 2 groups: children 6-12 years of age and adolescents 13-18 years of age. Children who meet eligibility requirements will be randomized to receive a rapid-dissolving oral dose of montelukast or placebo. Participants will be given a physical exam, have FEV1 measurements and clinical asthma scores recorded pre- and post- completion of a nebulized albuterol treatment of 0.1 mg/kg/dose (min 2.5 mg/dose). Blood samples for PK analysis will be collected prior to study drug administration and at predetermined time intervals to determine the plasma level of montelukast. In addition, a blood sample will be obtained for genetic study of polymorphisms of CYP3A4, CYP3A5, and CYP2C9.

Conditions

Status Asthmaticus; Asthma

Keywords

Montelukast; Albuterol; Status Asthmaticus; Asthma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Sterile Water

Sterile water

Group Type: SHAM_COMPARATOR

sterile water

Intervention Type: OTHER

sterile water

Montelukast

10mg rapid dissolving granules in sterile water orally once

Group Type: ACTIVE_COMPARATOR

Montelukast

Intervention Type: DRUG

10 mg rapid dissolving granule in sterile water orally once

Interventions

Montelukast

10 mg rapid dissolving granule in sterile water orally once

Intervention Type: DRUG

sterile water

sterile water

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Participant's parent/legal guardian must give written informed consent and written assent must be obtained form the subject prior to study participation.

1. Obtain consent of the parent/legal guardian using a signed consent form;

2. Obtain assent form minors between the ages of 7-13 using a signed assent form;

3. Obtain assent from minors between the ages of 14-17 by having the subject sign the consent formed signed the parent / legal guardian (Or based on the assessment by the Primary Investigator that the patient is unable to comprehend the study as written in the consent form document, the patient may document assent by signing the assent form).

• Participant, male or female, must be 6 to 18 years of age.
• Participant must have a history of reactive airway disease (RAD) or asthma and must currently be admitted for an acute exacerbation of RAD or asthma.
• Primary physician must believe that patient would benefit from improved bronchodilation and improvement in clinical asthma severity score.
• Participant must have received standard therapy for status asthmaticus:

1. Oxygen as needed

2. >3 nebulized albuterol treatments of at least 2.5mg/dose

3. Methylprednisolone or prednisone loading dose of 2mg/kg

4. Ongoing methylprednisolone therapy @ 0.5mg/kg every 6 hours

• Participant must have received steroids at least 6 hours prior to their inclusion, and must still require nebulized albuterol at least every 2 hours, as determined by PICU team in accordance with the PICU standard for evaluating and treating patients with RAD or asthma exacerbations.
• Participant must have an indwelling catheter in place from which to obtain blood specimens. Catheter may be peripheral or central, arterial or venous.

Exclusion Criteria

• Known hypersensitivity to montelukast
• Chronic lung disease other than RAD or asthma
• Known renal disease
• Known hepatic disease
• Cardiac or pulmonary congenital anomalies
• Known immunologic disorders other than allergy and atopy
• Other explanations for respiratory distress
• Use of leukotriene modifiers within 2 weeks of the acute presentation
• Pregnant females
• Intubated patients
• Inability to participate in portable spirometry for FEV1 measurement

• Minimum Eligible Age: 6 Years
• Maximum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Pediatric Pharmacology Research Units Network

NETWORK

Sponsor Role: collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

Sponsor Role: lead

Responsible Party

University Hospitals Case Medical Center

Principal Investigators

Jeffrey Blumer, MD

Role: PRINCIPAL_INVESTIGATOR

PPRU

Locations

Rainbow Babies and Children's Hospital

Cleveland, Ohio, United States

Site Status: RECRUITING

Countries

United States

Facility Contacts

Eloise Lemon, RN

Role: primary

Other Identifiers

PPRU 10856

Identifier Type: -

Identifier Source: org_study_id